Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study

NEXT STORY
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY
PREV STORY
Molecular Templates, Inc. Reports Fourth Quarter 2018 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ERBA Diagnostics, Inc. Announces Notice of Noncompliance With NYSE MKT Continued Listing Standards

MIAMI, Aug. 26, 2016 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (NYSE:ERB) (the “Company”), a ...

author_avatar
NASDAQ Market News

Mesoblast Corporate Review

NEW YORK and MELBOURNE, Australia, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast will enter ...

author_avatar
NASDAQ Market News

Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the American College of Surgeons Clinical Congress 2016

SAN RAMON, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a ...

author_avatar
NASDAQ Market News